Evidence map›Paper›PMID 39738166›Full record

ArticleScientific reports2024

Factors affecting fatigue progression in multiple sclerosis patients.

Dima Machtoub, Callie Fares, Hassan Sinan, Moustafa Al Hariri, Rim Nehme, Joelle Chami, Ronny Joukhdar, Raya Tcheroyan, Salim Adib, Samia J Khoury

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Fatigue and contributing factors in relapsing-remitting multiple sclerosis: a descriptive study based on the comprehensive fatigue assessment battery for multiple sclerosis (CFAB-MS).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dima Machtoub *Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Callie Fares *Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon.
Hassan SinanJohn Hopkins School of Medicine, Baltimore, MD, USA.
Moustafa Al HaririCollege of Medicine, QU Health Sector, Qatar University, Doha, Qatar.
Rim NehmeFaculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Joelle ChamiFaculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Ronny JoukhdarFaculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Raya TcheroyanDepartment of Internal Medicine, Cooper University Hospital, Camden, NJ, USA.
Salim AdibDepartment of Public Health, American University of Beirut, Beirut, Lebanon.
Samia J KhouryNehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Riad El-Solh, PO Box 11-0236, 1107 2020, Beirut, Lebanon. sk88@aub.edu.lb.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fatigue is one of the most prevalent and disabling symptoms among patients with MS, but there is limited research investigating the longitudinal determinants of fatigue progression. This study aims to identify the sociodemographic, behavioral and clinical characteristics, and therapeutic regimens that are correlated with worsening fatigue over time in patients diagnosed with MS. This is a retrospective chart review of 483 patients. The primary outcome was a change in the Modified Fatigue Impact Scale-5 (MFIS-5) score from first to last visit during the study interval, from November 2018 to November 2020. The study found that progressive MS subtypes, worsening depression, worsening pain, use of antidepressants, and use of fatigue medications were significantly associated with negative fatigue outcomes. Meanwhile age, sex, smoking frequency, use of pain medications, disease-modifying therapies, BMI, number of relapses, visits, steroid courses, and co-morbidities did not show an association. The clinical characteristics associated with worsening fatigue include progressive MS subtypes, worsening depression, worsening pain, use of antidepressants, and use of fatigue medications. Further studies are needed in order to elucidate a causal relationship and determine whether the management of fatigue in patients with MS should include interventions that address the aforementioned variables to optimize patient care and improve quality of life.

Indexed as

Disease ProgressionFatigueMultiple SclerosisAdultAntidepressive AgentsDepressionFemaleHumansMaleMiddle AgedPainQuality of LifeRetrospective StudiesAntidepressive AgentsDepressionFatiguePainProgressive MSRelapse-remitting MS

Identifiers

PMID39738166
PMCPMC11686268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.